Fidarestat，10MG，SML3973-10MG，Sigma

Biochem/physiol Actions

Active site-targeting, potent and selective aldose reductase (AR) inhibitor with >100-fold selectivity over aldehyde reductase (AHR).



Fidarestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Fidarestat has recently been shown to prevent inflammatory signals (TNF-α, LPS) that cause cancer (colon, breast, prostate and lung), metastasis, asthma, and other inflammatory diseases, as well as being useful for treatment of diabetic neuropathy.